Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Suganami · SciRah

Researcher profile · Semantic Scholar

H. Suganami

Share profile

H. Suganami — researcher profile on SciRah

h-index: 25
Works: 95
Citations: 2,553

Most-cited papers

O R I G I N a L I N V E S T I G a T I O N Open Access
K. Kaku, H. Watada, Y. Iwamoto, K. Utsunomiya +7 more
182 citations
Semantic Scholar
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
S. Ishibashi, S. Yamashita, H. Arai, E. Araki +4 more
2016Atherosclerosis181 citations Open access
Semantic Scholar
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
A. Nakajima, Yuichiro Eguchi, M. Yoneda, Kento Imajo +7 more
2021Alimentary Pharmacology and Therapeutics177 citations Open access
Semantic Scholar
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
E. Araki, S. Yamashita, H. Arai, K. Yokote +9 more
2018Diabetes Care148 citations
Semantic Scholar
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
S. Ishibashi, H. Arai, K. Yokote, E. Araki +2 more
2017Journal of Clinical Lipidology138 citations Open access
Semantic Scholar
One‐year clinical evaluation of 0.4% ripasudil (K‐115) in patients with open‐angle glaucoma and ocular hypertension
H. Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Y. Kuwayama +4 more
2016Acta ophthalmologica130 citations Open access
Semantic Scholar
Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
H. Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Y. Kuwayama +3 more
2015JAMA ophthalmology127 citations Open access
Semantic Scholar
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
H. Arai, S. Yamashita, K. Yokote, E. Araki +2 more
2018Journal of atherosclerosis and thrombosis116 citations Open access
Semantic Scholar
Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study
H. Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Y. Kuwayama +3 more
2015Acta ophthalmologica114 citations Open access
Semantic Scholar
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
H. Arai, S. Yamashita, K. Yokote, E. Araki +2 more
2017Atherosclerosis111 citations Open access
Semantic Scholar
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
Y. Tanizawa, K. Kaku, E. Araki, K. Tobe +7 more
2014Expert Opinion on Pharmacotherapy78 citations
Semantic Scholar
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
S. Morikawa, M. Umetani, S. Nakagawa, Hiroyuki Yamazaki +6 more
2000Journal of atherosclerosis and thrombosis75 citations Open access
Semantic Scholar
Restricted mean survival time as a summary measure of time‐to‐event outcome
T. Hasegawa, Saori Misawa, S. Nakagawa, Shinichi Tanaka +6 more
2020Pharmaceutical statistics57 citations
Semantic Scholar
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
K. Yokote, S. Yamashita, H. Arai, E. Araki +2 more
2019International Journal of Molecular Sciences57 citations Open access
Semantic Scholar
Stimulation of cell proliferation and autoregulation of elastin expression by elastin peptide VPGVG in cultured chick vascular smooth muscle cells
H. Wachi, Yoshiyuki Seyama, S. Yamashita, H. Suganami +4 more
1995FEBS Letters56 citations Open access
Semantic Scholar
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
S. Yamashita, H. Arai, K. Yokote, E. Araki +2 more
2018Journal of Clinical Lipidology44 citations Open access
Semantic Scholar
Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study
Hiroko Nakagawa, N. Koizumi, Naoki Okumura, H. Suganami +1 more
2015PLoS ONE44 citations Open access
Semantic Scholar
Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
I. Matsuba, Ren Matsuba, S. Ishibashi, S. Yamashita +4 more
2018Journal of Diabetes Investigation42 citations Open access
Semantic Scholar
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
E. Araki, S. Yamashita, H. Arai, K. Yokote +9 more
2019Diabetes, obesity and metabolism41 citations Open access
Semantic Scholar
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
H. Ginsberg, N. Hounslow, Y. Senko, H. Suganami +6 more
2022Diabetes Care37 citations Open access
Semantic Scholar
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
S. Yamashita, H. Arai, K. Yokote, E. Araki +4 more
2019International Journal of Molecular Sciences37 citations Open access
Semantic Scholar
QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys.
Hiroyuki Sasaki, N. Shimizu, H. Suganami, Keiji Yamamoto
2005Journal of Pharmacological Sciences37 citations Open access
Semantic Scholar
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials
K. Yokote, S. Yamashita, H. Arai, E. Araki +4 more
2021Cardiovascular Diabetology36 citations Open access
Semantic Scholar
QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation.
Hiroyasu Miyazaki, Hiroyuki Watanabe, T. Kitayama, M. Nishida +4 more
2005Journal of Pharmacological Sciences33 citations Open access
Semantic Scholar
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
M. Ouchi, K. Oba, K. Kaku, H. Suganami +10 more
2018Diabetes, obesity and metabolism26 citations Open access
Semantic Scholar
Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin.
Akihiro Yoshida, Y. Matsubayashi, T. Nojima, H. Suganami +6 more
2019Journal of Clinical Endocrinology and Metabolism25 citations Open access
Semantic Scholar
Regional distribution of two related Northeast Asian genotypes of JC virus, CY-a and -b: implications for the dispersal of Northeast Asians.
Huai-Ying Zheng, Peng-Yun Zhao, H. Suganami, Yasuo Ohasi +6 more
2004Microbes and infection21 citations Open access
Semantic Scholar
Role of fatty liver in the association between obesity and reduced hepatic insulin clearance.
Y. Matsubayashi, Akihiro Yoshida, H. Suganami, Hajime Ishiguro +6 more
2017Diabetes & Metabolism20 citations Open access
Semantic Scholar
Genetic diversity of JC virus in the Saami and the Finns: implications for their population history.
H. Ikegaya, Huai-Ying Zheng, P. Saukko, Leena Varesmaa-Korhonen +8 more
2005American Journal of Physical Anthropology20 citations
Semantic Scholar
Ripasudil-brimonidine Fixed-dose Combination vs. Ripasudil or Brimonidine; Two Phase 3 Randomized Clinical Trials.
H. Tanihara, Tetsuya Yamamoto, M. Aihara, K. Kawakita +4 more
2022American journal of ophthalmology-glaucoma18 citations Open access
Semantic Scholar
Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
Y. Matsubayashi, Akihiro Yoshida, H. Suganami, T. Osawa +6 more
2019Diabetes, obesity and metabolism18 citations Open access
Semantic Scholar
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe
M. Harada-Shiba, J. Kastelein, G. Hovingh, Kausik K. Ray +6 more
2017Journal of atherosclerosis and thrombosis18 citations Open access
Semantic Scholar
Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
K. Nunoi, Yuichi Sato, K. Kaku, Akihiro Yoshida +1 more
2018Endocrinology, Diabetes & Metabolism17 citations Open access
Semantic Scholar
Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
M. Harada-Shiba, O. Arisaka, A. Ohtake, T. Okada +1 more
2016Journal of atherosclerosis and thrombosis17 citations Open access
Semantic Scholar
Correlation between Climate and Crime in Eastern Tokyo
H. Ikegaya, H. Suganami
200816 citations
Semantic Scholar
Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
H. Tanihara, Tetsuya Yamamoto, M. Aihara, N. Koizumi +15 more
2023Advances in Therapy15 citations Open access
Semantic Scholar
Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
Y. Terauchi, Hisataka Fujiwara, Yuji Kurihara, H. Suganami +4 more
2019Journal of Diabetes Investigation15 citations Open access
Semantic Scholar
Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver
N. Hounslow, S. Mair, H. Suganami, M. Nakamura
2018Atherosclerosis Supplements15 citations
Semantic Scholar
The confidence interval of allelic odds ratios under the Hardy-Weinberg disequilibrium
Yasunori Sato, H. Suganami, C. Hamada, I. Yoshimura +3 more
2006Journal of Human Genetics14 citations
Semantic Scholar
Designing a multistage, SNP-based, genome screen for common diseases
Yasunori Sato, H. Suganami, C. Hamada, I. Yoshimura +2 more
2004Journal of Human Genetics13 citations
Semantic Scholar
Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
T. Nojima, Y. Matsubayashi, Akihiro Yoshida, H. Suganami +6 more
2020Diabetic Medicine12 citations Open access
Semantic Scholar
Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
K. Tobe, H. Suganami, K. Kaku
2017Journal of Diabetes Investigation11 citations Open access
Semantic Scholar
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study
H. Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi +28 more
2024Graefe's Archive for Clinical and Experimental Ophthalmology10 citations Open access
Semantic Scholar
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
K. Tsujita, K. Yokote, Junya Ako, R. Tanigawa +2 more
2023Journal of atherosclerosis and thrombosis10 citations Open access
Semantic Scholar
A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters
K. Yokote, S. Yamashita, H. Arai, E. Araki +2 more
2018Atherosclerosis Supplements10 citations
Semantic Scholar
Pemafibrate Minimally Affected the Systemic Exposure of Statins, and Vice Versa, in Healthy Male Volunteers
N. Hounslow, H. Suganami, M. Nakamura
2018Atherosclerosis Supplements10 citations
Semantic Scholar
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Takahiro Abe, Y. Matsubayashi, Akihiro Yoshida, H. Suganami +8 more
2017Diabetes & Metabolism10 citations
Semantic Scholar
QT PRODACT: inter- and intra-facility variability of the action potential assay using isolated guinea-pig papillary muscles.
Ryuzaburo Yamazaki, Masayuki Yamada, Kazuo Kobayashi, S. Kitani +5 more
2005Journal of Pharmacological Sciences9 citations Open access
Semantic Scholar
Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
K. Nunoi, Yuichi Sato, K. Kaku, Akihiro Yoshida +1 more
2019Diabetes, obesity and metabolism8 citations Open access
Semantic Scholar
Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes
Y. Matsubayashi, T. Nojima, Akihiro Yoshida, H. Suganami +5 more
2018Diabetes7 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Araki×14
Invite
E. Araki — researcher profile on SciRah
K. Yokote×13
Invite
K. Yokote — researcher profile on SciRah
K. Kaku×12
Invite
K. Kaku — researcher profile on SciRah
S. Ishibashi×12
Invite
S. Ishibashi — researcher profile on SciRah

×12

Invite

S. Yamashita — researcher profile on SciRah

Invite

H. Arai — researcher profile on SciRah

Akihiro Yoshida×9

Invite

Akihiro Yoshida — researcher profile on SciRah

Invite

T. Nojima — researcher profile on SciRah

Invite

H. Tanihara — researcher profile on SciRah

Y. Matsubayashi×6

Invite

Y. Matsubayashi — researcher profile on SciRah

Invite

K. Fujihara — researcher profile on SciRah

Shiro Tanaka×5

Invite

Shiro Tanaka — researcher profile on SciRah